Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think it means VEC won or at least have won someeeee-thing... but by nomeans sure!
As there hasn't been an RNS... maybe even VEC aren't sure what to make of this!!!!!
https://law.justia.com/cases/federal/district-courts/delaware/dedce/1:2016cv00638/59932/254/
You will need to click the download PDF icon to read the report.
80p is the resistance and no mistake.
Uncertainty over GSK outcome, uncertainty over Hikma link up and US acceptance, uncertainty over Brexit.
All-in-all this is bearing up quite well.
On a flat day for Markets & , although volume is relatively low, our recovery ( or is it a re rating) continues , for now.
I appreciate that I am a relative newbie having acquired my holding via SKP ( & adding more recently in the 70s) but long term holders here (if there are any left) must be feeling encouraged.It would be a pity to fall to a low ball bid but at least we would be out of our misery .
the wait on the gsk outcome in the US seems never ending, do we have any clues as to when the outcome will be known ?
ow.ly/VLaJ30naPow
Resistance broken up up up
bagger today lol
Zak Mir
? @ZaksTradersCafe
Island reversal on #VEC 80p neckline resistance
Bagged a few at 75p - nice gap-up today - 120s??
It has been a long time coming but I do believe that todays RNS is positive -which with view to The Markets dislike/distrust of all things Vec is likely to result in a reduction in our SP.
MrBB I do believe your going to be proven very right indeed...
I am sure that Vec will,one day, issue a truly positive RNS giving we long suffering shareholders encouragement .Perhaps 2019 will be our year ,although ,if we proceed with our litigation in the US ,we are less likely now to prevail & withdrawing maybe our best bet .
13 large buys occurred between 9 &10am on Friday, but were not recorded until well after the close. Those 13 buys came to almost 5 million shares, reported as costing up to 78.3p per trade
Those trades brought the volumes for the day to a reported 6,325,920 shares traded.
The auction UT was reported as 73p. But in the light of those very late reported trades... the final sp was also changed to well above the closing 'ask' ... to 77.75p. We will have to see if this is indicative of something positive in the offing, if it is ... that something looks like it could be good news!
Mmm... not much to see here after all. Volumes turned out low, imo the drop was an overreaction anyway so probably a combination of a retrace and bottom fishers or one of the funds increasing holdings on the back of the drop... maybe with an RNS appearing in the next few days.
Strange sp behaviour and It does like something is going on, not just the rise for no apparent reason... but also unusually high volumes for this time of the day! Weird sentiment also that the partnership news which paves the way for a major boost into a very lucrative market only caused a slight uptick in the sp... and yet the bad piece of news concerning what would have beeen a very tiny niche market and which trial failure was always such a strong possibility ... should cause such a large drop.
Perhaps our firm SP & recovery from its lows on Monday suggest that the Judge knows the verdict & is trading ahead of the news - or is that illegal-nowadays ?
(Note the USA trial date seems to have now reverted from next month back to April next year)
If we go to news flow, clearly, this result is disappointing. We've had a good string of more positive data in the last few months: VR647 Phase II results; a good set of interim results; and the positive results of the partnering of the Open-Inhale-Close device with Hikma. I think the market, as I said before, we had flagged that this was a riskier study. But when I look forward in 2019, I firmly believe the probability of success lies more in our favor looking forward. We have good progress with the -- our partnering with Hikma on VR315 on the clinical trial repeat program, and we look forward to that reading out in the resubmission. We look forward to accelerating essentially the VR647 program. And our team's focus can switch entirely onto that. We will be giving further disclosure on the enhanced reformulated repurpose 3 programs we touched on in September. And we're looking ideally to see if we could get accelerated orphan drug disease designation for 1, 2, possibly 3 of those programs before the end of next year. Novartis are continuing to progress with the asthma triple program for Europe, QVM149, and we should see the Phase III results next year and see that program being submitted. And as you know, the original clinical trial -- sorry, the trial date for the U.S. GSK patent litigation has now moved from what was originally scheduled from December to April next year, and so we should see that clinical trial outcome coming through, hopefully, in the first half of next year. On top of that, we also have business updates. We'll provide a trading update and further nuance on the R&D guidance in January, with preliminary results in March and interim results in September. So as I said, I think the risk there in associated upside is more in our favor now, and 475 was always like a slight overhang in terms of potential risk looking forward with that removed. I think we can look forward to hopefully a stronger string of results going forward into 2019.
... today but they had already warned that the bar had been set very high so not entirly unexpected. Would have been good if it had worked but as it wasn't gonna be a huge market so It'll possibly have ore of a downer effect on sentiment rather than any long term detriment to the financial fundamentals. However it's possible it's now become a tad more important to win the IP case... losing that on top of this would def not be seen as good! GLA.
Having spent the weekend studying it I cannot see how we can lose-the Yanks love an underdog ,& boy,are we an underdog !
... makes for interesting weekend reading! https://insight.rpxcorp.com/litigation_documents/12225755
Thnx Lindon -I thought the jury trial was this week & I appreciate that the Judge will now need to research & deliberate before delivering his opinion & ,I am sure, if it does not go the way if GSK , that they will appeal his decision -thereby wasting more time & money . Our announcing our collaboration with HIK to create competing generic products to their Ellipta range will no doubt deepen their resolve to put us in our place . Let’s hope we become the mouse that roared !
MrBB... this one isn't a jury trial and although a 5 day window was allowed it may have finished well before today. It's a hearing in front of an appointed judge specialised in IP protection law. I think that should actually be seen as a good thing because these sorts of cases are normally far too complex for normal public juries to get their heads around!
Which makes it seem more unreal for me that VEC instigated a trial in the states, which IS a trial by jury. This London one was brought about by GSK... seemingly in retaliation for VEC's initial action which is to sue them in the states. VEC are 'defendants' in this one!
These cases, which ARE normally heard in front of a specialist judge, are normally decided by prior case law. This also usually means that the judge will take several weeks to review similar cases before coming back to court to hand down his/her judgment and announcing who has ' 'won'. When that court is reconvened he will announce all the reference and case history work that he's waded through in arriving at the final decision. Hopefully not.... but It could even be next year before we hear any more on this one.
I dont understand how the outcome of cases such as ours, ie with a Jury, are determined & i appreciate that the general view is that the outcome wont be known for some weeks.
However,I would have thought that the presence of a Jury would result in the Judge directing the Jury in his summing up ( presumably today ,if it hasnt already happened) & the Jury then deliver their verdict - resulting in the outcome being known much sooner-ie possibly today ?
Excuse my ignorance !